Pharmacogenomics test coverage and reimbursement are major obstacles to clinical uptake. Several early adopter programs have been successfully initiated through dedicated investments by federal and...

The incorporation of personalized medicine interventions into routine healthcare constitutes an opportunity to improve patients' quality of life, as it empowers implementation of innovative, indivi...

Pharmacovigilance is a critical component of medication safety. Despite rigorous evaluation of new drugs during clinical trials, some adverse effects might only be identified once pharmaceuticals are used by a larger population for a longer duration. Adverse drug reactions cause negative healthcare outcomes and in severe cases, may lead to hospital admissions, delayed hospital discharges, or deaths. Adverse event reports submitted to pharmacovigilance programs by healthcare professionals and consumers are a key source of information regarding previously unrecognized detrimental effects. Pharmacogenetic markers that indicate how particular genes impact an individual’s response to medication can help explain some idiosyncratic adverse reactions. Incorporating pharmacogenomic guidance in prescribing is proven to decrease the incidence of adverse reactions and improve clinical outcomes. However, this information is not yet routinely included in incident reports. In this era of precision medicine, when prescribing can be tailored to the individual, pharmacogenomic test results yield valuable data that can enhance both individual and population health. Furthermore, advanced artificial intelligence (AI) and machine learning (ML) methods facilitate analysis of complex genetic data, revealing insights not previously available. This white paper outlines current pharmacovigilance and pharmacogenomic practices and recommends that pharmacovigilance programs include pharmacogenomics as a crucial data point in their investigations.

In this Perspective, the authors discuss the state of pharmacogenomics testing addressing a number of advances, challenges and barriers, including legal ramifications, changes to the regulatory lan...

Aim: To assess the knowledge, attitudes, and practices of the healthcare professionals working at Children's Cancer Hospital Egypt regarding pharmacovigilance (PV) and adverse drug reaction (ADR) r... Plain language summary Since no medication is completely safe, many of them are associated with multiple adverse reactions that may affect patients' health in terms of morbidity and, even worse, mo...

Background Selective serotonin reuptake inhibitors (SSRI) are commonly used for the treatment of depression and anxiety. Inhibition of serotonin reuptake in platelets increases bleeding risk in patients taking SSRIs. Case Here, we present the case of a 52-year-old patient who developed severe postsurgical bleeding requiring blood transfusion following panniculectomy. Conclusion SSRI-induced bleeding is dose-related and strongly influenced by individual variations in drug metabolizing enzymes and transporters. Video abstract Supplementary file1 (MP4 8441 KB)